Healthcare / BiotechnologyNasdaqGM
$4.33
-0.20 (-4.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-37.6M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$243M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-29.2%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2012–2025 · 13 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-57.4M · FCF $-56.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | $2.9M | — | — |
| Net Income | $-57.4M | $-57.4M | $-44.6M | $-40.4M | $-66.0M | $-47.3M | $-34.0M | $-7.8M | $-20.7M | $-30.0M | $-28.5M | $-21.4M | $-3.3M | $-7.9M | $-8.0M |
| EBITDA | $-64.2M | $-64.2M | $-48.8M | $-43.3M | $-64.6M | — | — | — | — | — | $-28.6M | $-20.8M | $-7.5M | $-7.1M | $-7.9M |
| EPS | — | — | -2.17 | -3.57 | -5.86 | -4.21 | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | -257.1% | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | -113.4% | — | — |
| Balance Sheet | |||||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.08 | 0.06 | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 15.69 | 15.69 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||
| Free Cash Flow | $-56.5M | $-56.5M | $-35.9M | $-37.6M | $-26.6M | $-35.1M | $-24.3M | $-5.5M | $-23.4M | $-22.4M | $-24.0M | $-17.8M | — | — | — |
| Returns | |||||||||||||||
| ROE | -29.2% | -29.2% | -26.7% | -59.2% | -64.6% | -29.2% | -17.1% | 368.0% | -433.8% | -86.3% | -74.2% | -33.7% | -4.1% | 7.9% | 9.2% |
| Valuation | |||||||||||||||
| P/B | 1.18 | 1.18 | 0.76 | 0.34 | 0.33 | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||
| EPS Growth | — | — | 39.2% | 39.1% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.17 → n/d
Residual
+31.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.